| Fallacies from clinical trials | Percutaneous coronary intervention. | Califf R M (Durham, US) |
| The new 'universal' definition of myocardial infarction | What has changed? | Thygesen (Aarhus C, DK) |
| The new 'universal' definition of myocardial infarction | Decision limits and pitfalls of biomarkers. | Jaffe A (Rochester, US) |
| The new 'universal' definition of myocardial infarction | Implications for clinical practice. | Hamm C W (Bad Nauheim, DE) |
| The new 'universal' definition of myocardial infarction | Implications for clinical trials. | Simoons M L (Rotterdam, NL) |
| Clinical Trial Update I | Prasugrel Compared with Clopidogrel in Patients with ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.- Discussant. | Neumann F J (Bad Krozingen, DE) |
| Clinical Trial Update I | Impact of Major Adverse Cardiac Events and Major Bleeding on Overall Mortality in Patients with STEMI: the HORIZONS AMI Trial. | Mehran R (New York, US) |
| Clinical Trial Update I | Impact of Major Adverse Cardiac Events and Major Bleeding on Overall Mortality in Patients with STEMI: the HORIZONS AMI Trial - Discussant. | Califf R M (Durham, US) |
| Clinical Trial Update I | Polish-Italian-Hungarian Randomized Thrombectomy Trial (PIHRATE trial). | Dudek D (Krakow, PL) |
| Clinical Trial Update I | Polish-Italian-Hungarian Randomized Thrombectomy Trial (PIHRATE trial). - Discussant. | De Feyter P J (Rotterdam, NL) |
| Clinical Trial Update I | One-year results of the Combined Abciximab Reteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI) trial. - Discussant. | Weaver W D (Detroit, US) |
| Clinical Trial Update I | The effect of the pre-hospital initiation of a glycoprotein 2b/3a recepter blocker in patients undergoing primary angioplasty for acute myocardial infarction. Results of the Ongoing Tirofiban in Myocardial Infarction Evaluation (On-TIME) 2 Trial. - Discus | Ardissino D (Parma, IT) |
| Hot Line II | The SYNergy between Percutaneous Coronary Intervention and Cardiac Surgery (SYNTAX) Study. | Mohr F W (Leipzig, DE) |
| Hot Line II | The SYNergy between Percutaneous Coronary Intervention and Cardiac Surgery (SYNTAX) Study. | Serruys P W (Rotterdam, NL) |
| Hot Line II | The SYNergy between Percutaneous Coronary Intervention and Cardiac Surgery (SYNTAX) Study - Discussant - The cardiologist's point of view. | Hamm C W (Bad Nauheim, DE) |
| Hot Line II | The SYNergy between Percutaneous Coronary Intervention and Cardiac Surgery (SYNTAX) Study - Discussant - The surgeon's point of view. | Jones R H (Durham, US) |
| Hot Line II | LEADERS - Limus Eluted from A Durable versus Erodable stent coating (Randomized Comparison of a biolimus-A9 eluting stent with a sirolimus-eluting stent for percutaneous coronary intervention. | Windecker S (Bern, CH) |
| Hot Line II | LEADERS - Limus Eluted from A Durable versus Erodable stent coating (Randomized Comparison of a biolimus-A9 eluting stent with a sirolimus-eluting stent for percutaneous coronary intervention - Discussant. | Mauri L (Boston, US) |
| The new ESC guidelines | Acute Coronary Syndromes (ACS) with ST-elevation. | Van de Werf F (Leuven, BE) |
| Safety of drug-eluting stents: two years after Barcelona | Lessons from registries. | Harrington R A (Durham, US) |
| Safety of drug-eluting stents: two years after Barcelona | Latest data from randomised trials. | Kastrati A (Munchen, DE) |
| Safety of drug-eluting stents: two years after Barcelona | Antiplatelet therapy. | Jaffe R (Haifa, IL) |
| Hot Line III | The Effects of the Direct Lipoprotein -associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Athlerosclerotic Plaque. | Wijns W (Aalst, BE) |
| Hot Line III | The Effects of the Direct Lipoprotein -associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Athlerosclerotic Plaque - Discussant | Crea F (Roma, IT) |
| Hot Line III | Safety of the factor Xa inhibitor, Apixaban, in combination with antiplatelet therapy after acute coronary syndrome: Results of the APPRAISE-I dose guiding trial. | Alexander J (Durham, US) |
| Hot Line III | Safety of the factor Xa inhibitor, Apixaban, in combination with antiplatelet therapy after acute coronary syndrome: Results of the APPRAISE-I dose guiding trial - Discussant. | Van de Werf F (Leuven, BE) |
| Hot Line III | Main Results of the Tailoring Treatment with Tirofiban in patients showing Resistance to aspirin or Resistance to clopidogrel study (3T/2R). | Valgimigli M (Ferrara, IT) |
| Hot Line III | Main Results of the Tailoring Treatment with Tirofiban in patients showing Resistance to aspirin or Resistance to clopidogrel study (3T/2R) - Discussant. | Verheugt FWA (Nijmegen, NL) |
| Hot Line III | A Multicenter, Double blind, Randomized, Placebo Controlled Study to Measure the Effect of FX06 on Ischemia Reperfusion Injury in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (The F.I.R.E Trial). | Atar D (Oslo, NO) |
| Highlight Session | Acute Coronary Syndromes (ACS) . | Fox K A (Edinburgh, GB) |
| Optimal management of ST-elevation myocardial infarction patients on both sides of the Atlantic | Highlights of the new US ST-elevation myocardial infarction guidelines. | E M Antman (Boston, US) |
| Optimal management of ST-elevation myocardial infarction patients on both sides of the Atlantic | Highlights of the new European ST-elevation myocardial infarction guidelines. | F Van de Werf (Leuven, BE) |
| Optimal management of ST-elevation myocardial infarction patients on both sides of the Atlantic | Are there significant differences? | R G Wilcox (Nottingham, GB) |
| Optimal management of ST-elevation myocardial infarction patients on both sides of the Atlantic | When do we need a new update and on what specifically? | E R Bates (Ann Arbor, US) |
| Antithrombotic and antiplatelet treatment in coronary artery disease: 2008 | Non ST-elevation acute coronary syndrome. | D Ardissino (Parma, IT) |
| Antithrombotic and antiplatelet treatment in coronary artery disease: 2008 | ST-elevation myocardial infarction. | A Budaj (Warsaw, PL) |
| Antithrombotic and antiplatelet treatment in coronary artery disease: 2008 | Efficacy versus safety. | J-P Bassand (Besancon, FR) |
| Hot Line III | Discussant. | M S Marber (London, GB) |